The global continuous renal replacement therapy market size is anticipated to reach USD 2,603.8 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2023 to 2030. The primary driving factors for market growth are increasing prevalence of congestive heart failure and acute renal failure. The COVID-19 is expected to have a positive impact on market due to increasing prevalence of acute kidney injury. According to a WHO, acute kidney injury, a potentially life-threatening condition in which the kidneys cease working and uremic and fluid toxins build up in the body, is one of the many COVID-19 side effects. As a result, as the COVID-19 outbreak expands, demand for CRRT will continue to climb.

Over the forecast period, technological advancements are expected to be a crucial driver in the growth of the market. For example, in August 2020, Baxter International Inc., a global leader in acute care, announced that Regiocit, the company's replacement solution containing citrate for extracorporeal circuit regional citrate anticoagulation, has acquired an Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA). Regiocit is exclusively approved for use as a replacement solution in adult patients receiving Continuous Renal Replacement Therapy (CRRT) and who require regional citrate anticoagulation during the COVID-19 pandemic, according to the EUA.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Detailed Segmentation:

Product Insights

Based on product, the market is segmented into systems and consumables. The consumables segment held the largest revenue share of 60.6% in 2022 and is expected to grow at the fastest CAGR of 9.1% over the forecast period. The increase in the utilization of charcoal filters, haemofilter, fluid and other consumable products in CRRT has been a contributing factor to the segment growth. Hemofilters, often known as artificial kidneys, are made out of a hollowfiber membrane that decides how much solute and fluid is removed. For patients with significant renal illnesses, businesses like Baxter and Fresenius offer a variety of consumables across modalities. Although these products are inexpensive, they are frequently purchased as compared to other segments.

Modality Insights

Based on modality, the market is segmented into slow continuous ultra-filtration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). The continuous venovenous hemofiltration (CVVH) segment dominated the market and accounted for a revenue share of 31.6% in 2022. Over the projection period, the rising prevalence of fluid overload cases, which are commonly observed in acute kidney injury patients in critical care units, is predicted to move the CVVH segment forward. An article published by Elsevier stated that congestive heart failure accounted for approximately five percent of all-cause mortality among dialysis patients. This condition is closely associated with fluid overload, which will consequently lead to an increase in demand and usage of CVVH treatment.

Regional Insights

North America dominated the market and accounted for the largest revenue share of 36.5% in 2022. Key factor that is expected to contribute to the continuous renal replacement therapy market growth in this region is increasing prevalence of geriatric population base. with the increasing population being diagnosed with kidney disorders in the region, alternative and better methods are being followed more rigorously. Furthermore, the increasing adoption of sedentary lifestyles and unhealthy food habits is considered the highest rendering drivers for the growth of various lifestyle-related disorders such as kidney dysfunction, hypertension, and diabetes. For instance, according to the U.S. Department of Health and Human Services in 2021, more than 1 in 7 U.S. adults may have Chronic Kidney Disease (CKD), which is expected to drive market growth in North America.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030.

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Key Companies & Market Share Insights

With the increased demand for CRRT products, global manufacturers are speeding up manufacturing while also improving it with cost-effective solutions. For instance, in March 2022, Nipro, a leader in manufacturing of renal products, announced full-scale commercial launch of SURDIAL DX. It is a futuristic hemodialysis system that is designed to create optimal dialysis treatment.

In April 2022, Baxter International announced the FDA (510k) clearance of ST set used in continuous renal replacement therapy. It is pre-connected, extracorporeal, and uses a semipermeable membrane to purify blood and is used with PrisMax or Prismaflex.

Leading organizations in the market are enforcing improved product quality through mergers and acquisitions along with increasing awareness regarding diseases to support education for healthcare professionals. For instance, in June 2021, Fresenius Medical Care inaugurated its training center in Korea, to support education for healthcare professionals in critical care, renal care, and treatment strategies. 

Some of the prominent players in the global continuous renal replacement therapy market include:

• B. Braun Melsungen AG

• Baxter International, Inc.

• Fresenius Medical Care AG & Co. KGaA

• Asahi Kasei Corporation

• NIPRO Corporation

• Toray Medical Co., Ltd

• NxStage Medical, Inc.

• Medtronic PLC

Continuous Renal Replacement Therapy Market Segmentation

Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:

Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)

• System

• Consumables

Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2018 - 2030)

• Slow Continuous Ultra-Filtration (SCUF)

• Continuous Venovenous Hemofiltration (CVVH)

• Continuous Venovenous Hemodialysis (CVVHD)

• Continuous Venovenous Hemodiafiltration (CVVHDF)

Continuous Renal Replacement Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o China

o Japan

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.